Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
19,919,674
-
Total 13F shares
-
2,947,949
-
Share change
-
-1,407,244
-
Total reported value
-
$19,279,960
-
Put/Call ratio
-
52%
-
Price per share
-
$6.54
-
Number of holders
-
51
-
Value change
-
-$7,678,884
-
Number of buys
-
14
-
Number of sells
-
24
Institutional Holders of Karyopharm Therapeutics Inc. - Common Stock, $0.0001 par value per share (KPTI) as of Q3 2025
As of 30 Sep 2025,
Karyopharm Therapeutics Inc. - Common Stock, $0.0001 par value per share (KPTI) was held by
51 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,947,949 shares.
The largest 10 holders included
T. Rowe Price Investment Management, Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., VANGUARD GROUP INC, BlackRock, Inc., Catalio Capital Management, LP, Avidity Partners Management LP, MARSHALL WACE, LLP, C WorldWide Group Holding A/S, GEODE CAPITAL MANAGEMENT, LLC, and GROUP ONE TRADING LLC.
This page lists
51
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.